泌尿慢性盆腔疼痛综合征3年症状轨迹:MAPP症状模式研究
该多中心前瞻性队列纳入545例泌尿慢性盆腔疼痛综合征(UCPPS)患者,随访中位34个月,用功能聚类识别疼痛与排尿症状轨迹。约30%患者3年内疼痛和/或排尿症状改善;女性、睡眠较好、阿片类使用较少与疼痛改善相关,较年轻和基线膀胱镜治疗与排尿症状改善相关。
要点
- 约30%的UCPPS患者3年内疼痛和/或排尿症状改善。
- 女性、睡眠较好、阿片类使用较少与疼痛改善相关。
- 较年轻和基线膀胱镜治疗与排尿症状改善相关。
核心结论
- 约30%的UCPPS患者在3年内疼痛和/或排尿症状改善。
- 与改善相关的基线因素可能反映较轻或局限的表型及/或治疗效应。
研究设计与样本
- 多中心前瞻性队列研究(MAPP症状模式研究),纳入545例UCPPS患者(66%女性)。
- 随访中位34个月(IQR 23-35),完成4次每周run-in评估、基线及每季度随访至3年。
- 对盆腔疼痛严重度(PPS)和排尿症状严重度(USS)纵向变化评分分别进行功能聚类,分为改善组(Group 0)与未改善组(Group 1-3)。
主要发现
- PPS和USS各识别出4个轨迹聚类:中度改善(Group 0)、轻度改善(Group 1)、无变化(Group 2)、轻度加重(Group 3)。
- 18%的患者属于PPS中度改善组,19%属于USS中度改善组,总体30%患者改善。
- 女性、睡眠较好、阿片类使用较少与PPS改善(Group 0)相关。
- 较年轻和基线膀胱镜治疗与USS改善(Group 0)相关。
临床怎么用
- 对UCPPS患者可告知约30%在3年内症状改善,基线因素有助于识别可能改善者。
- 女性、睡眠较好、阿片类使用较少者疼痛改善可能性较高,或可据此分层管理。
- 较年轻及接受基线膀胱镜治疗者排尿症状改善可能性较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterise 3-year pelvic pain and urinary symptom trajectories and to identify baseline factors associated with urologic chronic pelvic pain syndrome (UCPPS) improvement. PATIENTS AND METHODS: The Trans-Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study was a multicentre, prospective cohort study of UCPPS, including interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome. Patients completed four weekly run-in assessments, baseline visit, and quarterly visits up to 3 years, providing clinical and patient-reported data. A functional clustering approach, applied separately to Pelvic Pain Severity (PPS) and Urinary Symptom Severity (USS) longitudinal change scores, was used to generate symptom trajectory clusters dichotomised as Group 0 'improvers' vs Groups 1-3 'non-improvers'. Logistic regression models explored baseline factors associated with improvement and included run-in period average and baseline scores to adjust for regression to the mean effects. RESULTS: A total of 545 patients (66% female) were followed for a median (interquartile range) of 34 (23-35) months. Four trajectory clusters were identified for each of PPS and USS, consistent with moderate improvement (Group 0), slight improvement (Group 1), no change (Group 2), and slight worsening (Group 3). In all, 18% and 19% of patients were in the moderately improved PPS and USS groups, respectively, representing 30% of patients overall. Female sex, better sleep, and less opioid use were associated with PPS improvement (Group 0); younger age and baseline cystoscopic treatment were associated with USS improvement (Group 0). CONCLUSION: In all, 30% of patients with UCPPS demonstrated improvement in pain and/or urinary symptoms over 3 years. Baseline factors associated with improvement may represent markers of a milder or localised phenotype and/or treatment effects.
引用
- Bradley CS, You M, Guo W, et al. Urologic chronic pelvic pain syndrome 3-year symptom trajectories: the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study. BJU Int. 2025. PMID: 41328479. doi:10.1111/bju.70087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。